Zydus Lifesciences Limited and its subsidiaries have successfully completed the subscription of equity shares in Torrent Urja 25 Private Limited. The company invested the remaining amount of Rs. 90.18 million on May 19, 2026, for the subscription of 90,17,848 equity shares under Tranche 2, 3, and 4. This investment represents 22.06% of the paid-up share capital of Torrent Urja 25.

The transaction was executed pursuant to the Share Subscription and Shareholders’ Agreements (SSSAs) previously entered into by the parties. Following this investment, the entire transaction of subscription of shares in Torrent Urja 25 has been consummated as of May 19, 2026. The investment underscores the company’s commitment to environmental, social, and governance (ESG) principles and aligns with its strategic objective of achieving carbon neutrality.

Investment Details

The investment was carried out in multiple tranches as per the terms of the SSSAs. The following table outlines the investment made across the different tranches:

Background

Earlier intimations dated May 28, 2025, and June 27, 2025, had detailed the structure of this investment. The first tranche saw an aggregate investment of Rs. 38.65 million for 38,64,792 equity shares. The recent completion of the subsequent tranches brings the total investment to Rs. 128.83 million for a total of 1,28,82,640 equity shares.

Zydus Lifesciences Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a 16.2% year-on-year increase in revenue from operations to Rs. 75,870 mn for Q4 FY26, while net profit rose 8.7% to Rs. 12,725 mn. For the full year FY26, revenue grew 16.8% to Rs. 2,71,484 mn and net profit increased 11.4% to Rs. 50,400 mn.

Key Board Decisions

The Board of Directors approved the audited financial results and recommended a dividend of Re. 1 per equity share (100%) for FY2025-26, subject to shareholder approval at the Annual General Meeting scheduled for August 11, 2026. The Board also approved a buyback of equity shares for an aggregate amount up to Rs. 11,000 mn at a price of Rs. 1,150 per share.

Operational Performance

EBITDA for Q4 FY26 stood at Rs. 25,544 mn, a 20.2% increase from the previous year, with margins expanding by 110 basis points to 33.7%. R&D investments for the quarter were Rs. 6,982 mn, accounting for 9.2% of revenues. The Consumer Wellness business led growth with a 61.1% YoY increase, while the India Formulations business grew 14% YoY.

The company noted that adjusted profit for the quarter excluded exceptional expenses related to a Mirabegron litigation settlement and impairment charges. Net Debt to Equity ratio as of March 31, 2026, was 0.16x.